Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Scheel

Showing results (151-160 of 169) with videos related to

Pageof 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2017
Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma PatientsDennis Plenker, Miriam Bertrand, Adrianus J de Langen, et al.
Cancer Immunology Research|October 11, 2019
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGFMariangela Di Tacchio, Jadranka Macas, Jakob Weissenberger, et al.
Nature Communications|June 29, 2026
Discovery of 5' NAD capped viral RNAs reveals evolutionary divergent 5' metabolite capping across hepacivirusesHelena S Larsen, Anna V Sherwood, Lizandro R Rivera-Rangel, et al.
Hepatology (Baltimore, Md.)|August 4, 2023
Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in miceAriane J Brown, John J Won, Raphael Wolfisberg, et al.
Cell Reports|May 31, 2023
Resistance to mesenchymal reprogramming sustains clonal propagation in metastatic breast cancerMassimo Saini, Laura Schmidleitner, Helena Domínguez Moreno, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2022
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitorsRichard Riedel, Jana Fassunke, Hannah L Tumbrink, et al.
Nature|July 5, 2023
Hepatitis C virus RNA is 5'-capped with flavin adenine dinucleotideAnna V Sherwood, Lizandro R Rivera-Rangel, Line A Ryberg, et al.
Nature|October 22, 2019
FSP1 is a glutathione-independent ferroptosis suppressorSebastian Doll, Florencio Porto Freitas, Ron Shah, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 7, 2019
"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracyEmina Torlakovic, Hyun J Lim, Julien Adam, et al.
Science Translational Medicine|June 16, 2017
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumorsDennis Plenker, Maximilian Riedel, Johannes Brägelmann, et al.
Pageof 17

Showing results (151-160 of 169) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2017
Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma PatientsDennis Plenker, Miriam Bertrand, Adrianus J de Langen, et al.
Cancer Immunology Research|October 11, 2019
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGFMariangela Di Tacchio, Jadranka Macas, Jakob Weissenberger, et al.
Nature Communications|June 29, 2026
Discovery of 5' NAD capped viral RNAs reveals evolutionary divergent 5' metabolite capping across hepacivirusesHelena S Larsen, Anna V Sherwood, Lizandro R Rivera-Rangel, et al.
Hepatology (Baltimore, Md.)|August 4, 2023
Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in miceAriane J Brown, John J Won, Raphael Wolfisberg, et al.
Cell Reports|May 31, 2023
Resistance to mesenchymal reprogramming sustains clonal propagation in metastatic breast cancerMassimo Saini, Laura Schmidleitner, Helena Domínguez Moreno, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2022
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitorsRichard Riedel, Jana Fassunke, Hannah L Tumbrink, et al.
Nature|July 5, 2023
Hepatitis C virus RNA is 5'-capped with flavin adenine dinucleotideAnna V Sherwood, Lizandro R Rivera-Rangel, Line A Ryberg, et al.
Nature|October 22, 2019
FSP1 is a glutathione-independent ferroptosis suppressorSebastian Doll, Florencio Porto Freitas, Ron Shah, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 7, 2019
"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracyEmina Torlakovic, Hyun J Lim, Julien Adam, et al.
Science Translational Medicine|June 16, 2017
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumorsDennis Plenker, Maximilian Riedel, Johannes Brägelmann, et al.
Pageof 17